Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa
Journal of Infectious Diseases, Volume 198, No. 4, Year 2008
Notification
URL copied to clipboard!
Description
Background. The efficacy of bacille Calmette-Guérin (BCG) may be enhanced by heterologous vaccination strategies that boost the BCG-primed immune response. One leading booster vaccine, MVA85A (where "MVA" denotes "modified vaccinia virus Ankara"), has shown promising safety and immunogenicity in human trials performed in the United Kingdom. We investigated the safety and immunogenicity of MVA85A in mycobacteria-exposed - but Mycobacterium tuberculosis-uninfected - healthy adults from a region of South Africa where TB is endemic. Methods. Twenty-four adults were vaccinated with MVA85A. All subjects were monitored for 1 year for adverse events and for immunological assessment. Results. MVA85A vaccination was well tolerated and induced potent T cell responses, as measured by interferon (IFN)-γ enzyme-linked immunospot assay, which exceeded prevaccination responses up to 364 days after vaccination. BCG-specific CD4+ T cells boosted by MVA85A were comprised of multiple populations expressing combinations of IFN-γ, tumor necrosis factor (TNF)-α, interleukin (IL)-2, and IL-17, as measured by polychromatic flow cytometry. IFN-γ-expressing and polyfunctional IFN-γ+TNF-α+IL-2+ CD4+ T cells were boosted during the peak BCG-specific response, which occurred 7 days after vaccination. Conclusion. The excellent safety profile and quantitative and qualitative immunogenicity data strongly support further trials assessing the efficacy of MVA85A as a boosting vaccine in countries where TB is endemic. Trial registration. ClinicalTrials.gov identifier: NCT00460590. © 2008 by the Infectious Diseases Society of America. All rights reserved.
Authors & Co-Authors
Hawkridge, Tony
South Africa, Observatory
South African Tuberculosis Vaccine Initiative
Scriba, Thomas J.
South Africa, Observatory
South African Tuberculosis Vaccine Initiative
Gelderbloem, Sebastian J.
South Africa, Observatory
South African Tuberculosis Vaccine Initiative
Smit, Erica
South Africa, Observatory
South African Tuberculosis Vaccine Initiative
Tameris, Michele D.
South Africa, Observatory
South African Tuberculosis Vaccine Initiative
Moyo, Sizulu
South Africa, Observatory
South African Tuberculosis Vaccine Initiative
Lang, Trudie A.
United Kingdom, Oxford
Nuffield Department of Medicine
Veldsman, Ashley
South Africa, Observatory
South African Tuberculosis Vaccine Initiative
Hatherill, Mark
South Africa, Observatory
South African Tuberculosis Vaccine Initiative
van der Merwe, Linda
South Africa, Observatory
South African Tuberculosis Vaccine Initiative
Fletcher, Helen A.
United Kingdom, Oxford
Nuffield Department of Medicine
Mahomed, Hassan
South Africa, Observatory
South African Tuberculosis Vaccine Initiative
Hill, Adrian V. S.
United Kingdom, Oxford
Nuffield Department of Medicine
Hanekom, Willem Albert
South Africa, Observatory
South African Tuberculosis Vaccine Initiative
Hussey, Greg Dudley
South Africa, Observatory
South African Tuberculosis Vaccine Initiative
McShane, Helen
United Kingdom, Oxford
Nuffield Department of Medicine
United Kingdom, Oxford
Churchill Hospital
Statistics
Citations: 167
Authors: 16
Affiliations: 3
Identifiers
Doi:
10.1086/590185
ISSN:
00221899
Research Areas
Cancer
Infectious Diseases
Study Approach
Qualitative
Quantitative
Study Locations
South Africa